The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survey of actionable driver mutations KRAS and EGFR in non–small cell lung cancer to evaluate coexisting splicing gene and pathway mutations: A CBioportal database analysis.
 
Zhaohui Arter
No Relationships to Disclose
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - BloosomHill therapeutics; Elevation Oncology; Lilly; MBrace Therapeutics; Nuvalent, Inc.; Turning Point Therapeutics
Honoraria - BMS; Daiichi Sankyo; Dava Oncology; Johnson & Johnson/Janssen; Pfizer; Pfizer
Consulting or Advisory Role - AnHeart Therapeutics; Daiichi Sankyo; Janssen; Pfizer; Takeda
Research Funding - ARIAD (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); BMS (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)